Share this article
Share this article
ResearchAndMarkets.com s offering.
Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women. Of total lung cancer incident cases, approximately 85% are the NSCLC subtype. NSCLC patients are usually diagnosed in the later stages of the disease, resulting in a poor prognosis. Since the last global market forecast (2015-2025), there have been significant changes in the treatment of patients with advanced disease, particularly in the metastatic setting.
Although NSCLC is still not considered curable, physicians are enthusiastic about the progress being made in this field. New agents provide more durable responses, as demonstrated by improvements in progression-free survival and overall survival. Progress is demonstrated by the introduction of checkpoint inhibitors into the first-line setting and multiple next-generation targeted therapeutics which have dram